Viral gastroparesis: a subgroup of idiopathic gastroparesis--clinical characteristics and long-term outcomes
- PMID: 9317072
Viral gastroparesis: a subgroup of idiopathic gastroparesis--clinical characteristics and long-term outcomes
Abstract
Objectives: Viral gastroparesis has been regarded as a subgroup of idiopathic gastroparesis.
Methods: We have reviewed the medical records of 143 patients diagnosed as having gastroparesis. Fifty-two patients were regarded as idiopathic in origin, of which 12 were identified as consistent with a postviral etiology. Their follow-up and current status were assessed by interview. Available for interview were 32 patients: 11 from the viral group and 21 from idiopathic group.
Results: All "viral gastroparesis" patients reported gradual improvement of their symptoms, no hospitalizations during the previous 6 months, stable weight, were not disabled, and remained professionally active. In comparison, 21 "idiopathic" patients had an indolent, slowly progressive clinical presentation. The idiopathic group had a significantly longer duration of illness (p < 0.05) with greater symptom score of abdominal pain, early satiety, and anorexia, and overall worse quality of life (p < 0.05).
Conclusions: A viral etiology should be considered in gastroparesis patients when their illness is characterized by an acute onset, initial severe illness and slow resolution toward a satisfactory quality of life. Idiopathic gastroparesis is a more slowly progressive illness, and patients remain significantly more symptomatic for a longer period of time.
Similar articles
-
Gastric electrical stimulation is an effective and safe treatment for medically refractory gastroparesis.Surgery. 2008 Oct;144(4):566-72; discussion 572-4. doi: 10.1016/j.surg.2008.06.024. Surgery. 2008. PMID: 18847640
-
Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review.Am J Gastroenterol. 1996 Oct;91(10):2174-8. Am J Gastroenterol. 1996. PMID: 8855743
-
Gastric electrical stimulation for children with intractable nausea and gastroparesis.J Pediatr Surg. 2008 Mar;43(3):437-42. doi: 10.1016/j.jpedsurg.2007.10.005. J Pediatr Surg. 2008. PMID: 18358278
-
Management of gastroparesis.Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):411-23. doi: 10.1586/17474124.2.3.411. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072389 Review.
-
Review article: gastroparesis.Aliment Pharmacol Ther. 2008 May;27(9):724-40. doi: 10.1111/j.1365-2036.2008.03637.x. Epub 2008 Feb 4. Aliment Pharmacol Ther. 2008. PMID: 18248660 Review.
Cited by
-
Predicting Response to Neuromodulators or Prokinetics in Patients With Suspected Gastroparesis Using Machine Learning: The "BMI, Infectious Prodrome, Delayed GES, and No Diabetes" Model.Clin Transl Gastroenterol. 2024 Sep 1;15(9):e1. doi: 10.14309/ctg.0000000000000743. Clin Transl Gastroenterol. 2024. PMID: 39320959 Free PMC article.
-
An overview of Ehlers Danlos syndrome and the link between postural orthostatic tachycardia syndrome and gastrointestinal symptoms with a focus on gastroparesis.Front Neurol. 2024 Aug 29;15:1379646. doi: 10.3389/fneur.2024.1379646. eCollection 2024. Front Neurol. 2024. PMID: 39268060 Free PMC article. Review.
-
Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19: Findings from RECOVER Initiative from 29 Hospitals in the US.medRxiv [Preprint]. 2024 Jul 9:2024.05.21.24307699. doi: 10.1101/2024.05.21.24307699. medRxiv. 2024. PMID: 38826331 Free PMC article. Preprint.
-
Single cell atlas of human gastric muscle immune cells and macrophage-driven changes in idiopathic gastroparesis.iScience. 2024 Jan 23;27(3):108991. doi: 10.1016/j.isci.2024.108991. eCollection 2024 Mar 15. iScience. 2024. PMID: 38384852 Free PMC article.
-
Botulinum Toxin A Use in the Gastrointestinal Tract: A Reappraisal After Three Decades.Gastroenterol Hepatol (N Y). 2023 Apr;19(4):198-212. Gastroenterol Hepatol (N Y). 2023. PMID: 37705841 Free PMC article.